<DOC>
	<DOCNO>NCT00719173</DOCNO>
	<brief_summary>RATIONALE : Antiemetic drug , aprepitant , may help lessen prevent nausea vomit patient undergoing chemotherapy . PURPOSE : This randomized clinical trial study aprepitant see well work compare placebo prevent nausea vomit patient undergo chemotherapy breast cancer .</brief_summary>
	<brief_title>Effect Aprepitant Cyclophosphamide Pharmacokinetics Patients With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate effect aprepitant cyclophosphamide 4-hydroxycyclophosphamide pharmacokinetics measure plasma AUC patient breast cancer . Secondary - To evaluate total control nausea vomiting , define vomit episode use rescue medication , 72 hour course 1 2 chemotherapy . OUTLINE : Patients randomize 1 2 treatment arm . - Arm I : Patients receive aprepitant 125 mg orally daily day 1 80 mg orally daily day 2 3 . Beginning 1 hour receiving aprepitant , patient receive infusion cyclophosphamide day 1 . During course 2 , patient crossover receive treatment ( placebo ) arm II . - Arm II : Patients receive placebo 125 mg orally daily day 1 80 mg orally daily day 2 3 . Beginning 1 hour receive placebo , patient receive infusion cyclophosphamide infusion day 1 . During course 2 , patient crossover receive treatment ( aprepitant ) arm I . Patients complete diary documenting nausea vomit day 1 , 2 , 3 course . Patients also complete The Functional Living Index-Emesis ( FLIE ) questionnaire document compliance , rescue antiemetic therapy , adverse effect record diary course . Information patient 's diary obtain coordinator via telephone day 4 course . Patients undergo blood sample collection periodically pharmacokinetic study via high performance liquid chromatography .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis breast cancer Planning receive cyclophosphamide 600 mg/m²1,000 mg/m² IV infusion No cyclophosphamide dose change course 1 2 PATIENT CHARACTERISTICS : Life expectancy ≥ 2 month ANC ≥ 1,500/μL Platelet count ≥ 100 x 10^9/L Hemoglobin ≥ 9.0 g/dL Serum creatinine ≤ 1.5 mg/dL AST/ALT ≤ 2 time upper limit normal Not pregnant nursing No contraindication aprepitant PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent medication CYP3A4 substrate , inhibitor , and/or inducer , exception dexamethasone contain part standard antiemetic regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>nausea vomit</keyword>
	<keyword>breast cancer</keyword>
</DOC>